The Future of BioPharma - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Future of BioPharma
Innovation resulting in improved productivity continues unabated and is a primary driver for many of the current biopharmaceutical trends. Innovation speeds discovery, drives down costs, and improves productivity.


Pharmaceutical Technology


Key micro-trends

Biosimilars

  • Expect more models and analytical methods for demonstrating biosimilarity and biochemical or biophysical characterization
  • Expect more established regulations, definitions, and standards for biosimilars and biosimilarity
  • Expect bioprocess tweaks allowing for fine-tuning of biosimilars to match innovator biologics
  • Expect more quality by design and design of experiments (DoE) for all products including biosimilars

Analytical methods; assays

  • Expect simpler assay processes that increase process knowledge and speed/simplify product release
  • Expect more convenient, high-throughput assays that assess physicochemical properties of IgG /mAb clones for high level expression and therapeutic efficacy
  • Expect more assays to demonstrate biosimilarity and analytics to demonstrate equivalent product quality

Biomanufacturing process improvements

  • Expect to do more with less—higher workloads, fewer staff, with demands for higher quality and shorter timeframes
  • Improved processing (especially downstream) will better handle 10g/L and greater expression levels
  • Improved upstream process efficiency will incrementally reduce costs, increase productivity while ensuring compliance and quality

Biomanufacturing downstream process improvements

  • Alternatives to Protein A will continue to be sought and developed
  • Need for better performing chromatography resins
  • Development of non-chromatographic recovery unit operations
  • Single-use equipment will make more inroads in downstream processing

Single-use biomanufacturing

  • More quality will be built into single-use systems and operations to further reduce regulatory activities/oversight
  • Problems of disposable bioreactors and devices will be addressed that are creating inconsistent growth because of changes in resins, film gamma irradiation, and cell line specificity
  • Expect more single-use downstream operations using membrane adsorbers
  • Expect emergence of flexible and modular biomanufacturing facilities
  • Expect better standards for leachables and extractables testing and for cell growth
  • Single-use devices facilitating large-scale bioproduction in China and other lesser-developed countries

Regulatory compliance

  • Expect processes and technologies that support lower costs of clinical and commercial supplies
  • Expect more continuous validation programs that link process development and manufacturing data
  • Expect more implementation of process controls such as process analytical technology (PAT)

Supply chain, raw materials; control and sourcing

  • Expect more development of international regulations for quality and raw materials sourcing
  • Expect more process controls that reduce impact of process or raw materials changes on quality
  • Expect decreased product defects as manufacturing facilities increase process control while lowering production costs.

Eric Langer, is president of BioPlan Associates, tel. 301.921.5979,
.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here